Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
Vale SA
VALE
KB Home
KBH
Apple
AAPL
US Stock MarketDetailed Quotes
KNSA Kiniksa Pharmaceuticals International
- 19.740
- +0.090+0.46%
Close Feb 14 16:00 ET
- 19.740
- 0.0000.00%
Post 16:20 ET
1.43BMarket Cap-164.50P/E (TTM)
20.320High19.580Low640.90KVolume19.920Open19.650Pre Close12.77MTurnover2.82%Turnover Ratio98.70P/E (Static)72.20MShares28.15052wk High3.26P/B447.99MFloat Cap16.56052wk Low--Dividend TTM22.69MShs Float32.880Historical High--Div YieldTTM3.77%Amplitude5.010Historical Low19.927Avg Price1Lot Size
About Kiniksa Pharmaceuticals International Company
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
Company Profile
SymbolKNSA
Company NameKiniksa Pharmaceuticals International
Listing DateMay 24, 2018
Issue Price18.00
Founded2024
CEOMr. Sanj K. Patel
MarketNASDAQ
Employees297
Fiscal Year Ends12-31
Address23 Old Bond Street,3rd Floor
CityLondon
ProvinceGreater London
CountryUnited Kingdom of Great Britain and Northern Ireland (the)
Zip CodeW1S 4PZ
Phone44-781-431-9100
Websitehttps://www.kiniksa.com
Company Executives
- Name
- Position
- Salary
- Sanj K. Patel
- Chief Executive Officer and Chairman of the Board
- 5.30M
- Michael R. Megna
- Chief Accounting Officer and Group Vice President, Finance
- --
- Mark Ragosa
- Senior Vice President and Chief Financial Officer
- --
- Eben Tessari
- Senior Vice President and Chief Operating Officer
- 1.75M
- Ross Moat
- Senior Vice President and Chief Commercial Officer
- --
- John F. Paolini, M.D.,PhD
- Senior Vice President and Chief Medical Officer
- 1.79M
- Cantey Boyd
- Director
- --
- G. Bradley Cole
- Independent Director
- 365.36K
- Dr. Richard S. Levy,M.D.
- Independent Director
- 459.75K
- Tracey L. McCain, Esq.
- Independent Director
- 365.36K
- Thomas R. Malley
- Independent Director
- 380.36K
- Kimberly J. Popovits
- Independent Director
- 362.66K
- Dr. Stephen R. Biggar,M.D.,PhD
- Independent Director
- 371.96K
- Dr. Barry D. Quart,Pharm.D.
- Independent Director
- 372.55K
- Dr. Felix J. Baker,PhD
- Lead Independent Director
- 411.06K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.